Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Ni...(ense (1361) (1175) (3...),Health

Date:11/4/2009

ense (1,361) (1,175) (3,421) (2,970) Amortization of purchased intangibles (1,027) (1,318) (3,227) (3,955) HeartWare transaction costs (394) - (4,925) - Impact of adoption of ASC 470-20 (768) (701) (2,235) (2,041) Unrealized gain on embedded derivative instrument on HeartWare loan 2,096 - 2,096 - ----- - ----- - Tax expense on a non-GAAP basis $(7,138) 34.0% $(4,672) 30.9% $(20,195) 34.1% $(12,759) 32.0% ======= ======= ======== ======== (1) Adjusted for the retrospective adoption of the accounting for convertible debt instruments that may be settled in cash upon conversion, including partial settlements, in accordance with ASC 470-20, Debt. The following table reconciles the guidance on a GAAP and non-GAAP basis for the periods shown below: THORATEC CORPORATION Reconciliation of GAAP to Non-GAAP Forward-Looking Guidance (Unaudited) (in thousands, except for per share data) Net income per diluted share For the Fiscal Year Ended 2009 reconciliation ------------------------------ From To ---- -- Net income per diluted share on a GAAP basis $0.41 $0.46 Share-based compensation expense 0.17 0.16 Amortization of purchased intangibles 0.13 0.13 HeartWare transaction costs 0.15 0.15
'/>"/>

SOURCE Thoratec Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA